Entera Bio (ENTX) AI Stock Analysis

• Market Cap: $74.75M
• Dividend Yield: N/A
• Average Volume (3M): 123.78K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.61
• Revenue Growth: 25.25%
• EPS Growth: 5.96%
• Country: US
• Employees: 18
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.07
• Shares Outstanding: 45,857,243
• 10 Day Avg. Volume: 240,874
• 30 Day Avg. Volume: 123,776
• PEG Ratio: 0.43
• Price to Book (P/B): 9.88
• Price to Sales (P/S): 440.99
• P/FCF Ratio: -11.70
• Enterprise Value/Market Cap: 0.94
• Enterprise Value/Revenue: 567.09
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -9.32
• 1Y Price Target: $10.00
• Price Target Upside: 513.50% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 45 Neutral
• Price Target: $1.50 ▼(-7.98% Downside)

Score is pressured primarily by very low and declining revenue, ongoing losses, and significant cash burn, which elevate dilution/funding risk. Technicals are also weak with the stock below key moving averages and negative MACD, despite oversold readings. Positives include low leverage, improved equity, and a favorable FDA Phase 3 agreement that modestly supports the outlook.

Positive Factors

Oral peptide delivery platform

Entera’s N-Tab oral peptide platform is a durable competitive asset: it targets the long-standing market barrier of injectable biologics, enabling once-daily oral dosing across multiple programs (EB613, EB612, GLP-2). Platform reuse can lower development cost and speed pipeline expansion if clinical efficacy holds.

Regulatory milestone for osteoporosis endpoint

The FDA’s broad qualification of total hip BMD and prior Phase 3 alignment for EB613 materially simplifies trial design and endpoints. This structural regulatory reform can reduce trial size, duration and cost, lowering development risk and improving the company’s odds of bringing an oral anabolic to market.

Low leverage and stronger equity base

Very low debt and a materially higher equity base provide financial flexibility and reduce bankruptcy risk versus highly leveraged peers. This durable balance-sheet strength supports continued R&D and makes strategic options (partnerships, non-dilutive deals) more viable ahead of potential approval or commercialization.

Negative Factors

Minimal and declining revenue

Revenue is negligible and falling, reflecting limited commercial traction and an inability to offset development costs. Over the medium term this increases dependence on external financing, reduces validation of market demand, and raises the bar for demonstrating a sustainable commercial business model post-approval.

Persistent cash burn

Consistent negative operating and free cash flow indicate the company is funding operations through capital markets rather than generating cash. This persistent burn pressures liquidity, can force financing before approvals, and increases dilution risk unless offset by partnerships or meaningful revenue growth.

Limited runway and funding risk

A runway only into mid-2026 creates a structural funding cliff before likely commercial revenue. This forces dependence on equity raises or deals around pivotal Phase 3 timing, which can dilute shareholders or delay development if market conditions are unfavorable, constraining strategic optionality.

Entera Bio Business Overview & Revenue Model

Company Description

Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally delivered large molecule therapeutics for unmet medical needs. The company's lead product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of non-union fractures. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.

How the Company Makes Money

Entera Bio generates revenue through the development and commercialization of its proprietary oral drug formulations. The company's key revenue streams include collaborations and licensing agreements with other pharmaceutical companies. These partners may provide upfront payments, milestone payments, and royalties based on the sales of successfully developed drugs. Entera Bio's business model relies heavily on research and development activities, strategic partnerships, and the potential commercialization of its pipeline products.

Entera Bio Financial Statement Overview

Summary

Entera Bio faces significant financial challenges, with persistent losses, negative cash flows, and dependency on external financing. The income statement shows erratic revenue growth and weak profit margins, while the balance sheet reflects moderate leverage but negative shareholder returns. Cash flow management issues further emphasize financial instability.

Income Statement

Entera Bio has struggled with profitability, evidenced by consistently negative net income and EBIT over the years. The gross profit margin is weak, and the net profit margin is negative due to significant operating losses. The revenue growth is erratic, with revenue fluctuating significantly, highlighting instability in revenue generation.

Balance Sheet

The company's financial stability is moderate with a low debt-to-equity ratio, indicating manageable leverage. However, the return on equity is negative due to net losses, which impacts shareholder value. The equity ratio suggests a reasonable proportion of assets financed by equity, but overall balance sheet performance is hampered by ongoing losses.

Cash Flow

Cash flow management presents challenges, with negative operating cash flow and free cash flow across periods, indicating cash burn issues. The free cash flow to net income ratio is also negative, reflecting inefficiencies in converting income into cash. Financing activities have been crucial for liquidity, highlighting dependency on external funding.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	124.00K	181.00K	0.00	134.00K	571.00K	365.00K
Gross Profit	0.00	9.00K	-56.00K	-31.00K	198.00K	65.00K
EBITDA	-7.54M	-9.54M	-8.80M	-12.87M	-12.16M	-11.11M
Net Income	-10.78M	-9.54M	-8.89M	-13.07M	-12.19M	-11.22M
Balance Sheet
Total Assets	17.41M	9.39M	11.77M	13.13M	25.99M	9.72M
Cash, Cash Equivalents and Short-Term Investments	8.57M	8.66M	11.02M	12.31M	24.89M	8.59M
Total Debt	211.00K	272.00K	390.00K	91.00K	302.00K	432.00K
Total Liabilities	2.17M	1.31M	1.38M	1.37M	3.42M	2.21M
Stockholders Equity	15.23M	8.08M	10.39M	11.75M	22.57M	7.51M
Cash Flow
Free Cash Flow	-7.34M	-6.82M	-7.33M	-12.55M	-9.08M	-10.61M
Operating Cash Flow	-7.26M	-6.82M	-7.31M	-12.50M	-9.06M	-10.56M
Investing Cash Flow	-86.65K	-3.00K	-17.00K	-102.00K	-17.00K	-53.00K
Financing Cash Flow	17.37M	4.48M	6.04M	13.00K	25.38M	4.05M

Entera Bio Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.63
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ENTX, the sentiment is Negative. The current price of 1.63 is below the 20-day moving average (MA) of 1.77, below the 50-day MA of 2.22, and below the 200-day MA of 2.06, indicating a bearish trend. The MACD of -0.17 indicates Positive momentum. The RSI at 41.08 is Neutral, neither overbought nor oversold. The STOCH value of 13.15 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ENTX.

Entera Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RPTX	58 Neutral	$112.08M	-1.53	-49.78%	―	-82.16%	14.58%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NRXP	50 Neutral	$63.65M	-0.91	―	―	―	-9.32%
ENTX	45 Neutral	$74.75M	-6.66	-99.43%	―	25.25%	5.96%
EQ	44 Neutral	$70.03M	-1.82	-90.24%	―	-90.43%	-382.07%
ATYR	42 Neutral	$70.34M	-0.86	-103.22%	―	-19.15%	10.90%
PLRX	42 Neutral	$80.50M	-0.46	-64.27%	―	―	14.19%

Entera Bio Corporate Events

Entera Bio Reports Q3 2025 Results and FDA Agreement

Entera Bio announced its third quarter 2025 financial results and business updates, highlighting significant progress in its oral peptide therapies. The company received FDA agreement for its EB613 Phase 3 study, marking a pivotal step in osteoporosis treatment. Phase 2 data showed promising efficacy in younger post-menopausal women, and preclinical data for oral GLP-2 and OXM programs were presented at major conferences. Financially, Entera reported a net loss of $3.2 million for the quarter, with cash reserves expected to support operations into mid-2026.

The most recent analyst rating on (ENTX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Entera Bio stock, see the ENTX Stock Forecast page.